Next Article in Journal
Click Decoration of Bombyx mori Silk Fibroin for Cell Adhesion Control
Next Article in Special Issue
Synthesis and Characterization of Novel Resveratrol Butyrate Esters That Have the Ability to Prevent Fat Accumulation in a Liver Cell Culture Model
Previous Article in Journal
Polyphenols vs. Coronaviruses: How Far Has Research Moved Forward?
Previous Article in Special Issue
Protective Effects of Some Grapevine Polyphenols against Naturally Occurring Neuronal Death
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 25
Issue 18
10.3390/molecules25184105
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Wine’s Phenolic Compounds and Health: A Pythagorean View

by
Francesco Visioli
1,2,*,
Stefan-Alexandru Panaite
1 and
Joao Tomé-Carneiro
2
1
Department of Molecular Medicine, University of Padova, Viale G. Colombo 3, 35121 Padova, Italy
2
IMDEA-Food, CEI UAM + CSIC, 28049 Madrid, Spain
*
Author to whom correspondence should be addressed.
Molecules 2020, 25(18), 4105; https://doi.org/10.3390/molecules25184105
Submission received: 14 August 2020 / Revised: 2 September 2020 / Accepted: 5 September 2020 / Published: 8 September 2020
(This article belongs to the Special Issue Benefits of the Mediterranean Diet–Wine Association: Role of Components)
Browse Figure
Review Reports Versions Notes

Abstract

:
In support of the J curve that describes the association between wine consumption and all-cause mortality, researchers and the lay press often advocate the health benefits of (poly)phenol consumption via red wine intake and cite the vast amount of in vitro literature that would corroborate the hypothesis. Other researchers dismiss such evidence and call for total abstention. In this review, we take a skeptical, Pythagorean stance and we critically try to move the debate forward by pointing the readers to the many pitfalls of red wine (poly)phenol research, which we arbitrarily treat as if they were pharmacological agents. We conclude that, after 30 years of dedicated research and despite the considerable expenditure, we still lack solid, “pharmacological”, human evidence to confirm wine (poly)phenols’ biological actions. Future research will eventually clarify their activities and will back the current recommendations of responsibly drinking moderate amounts of wine with meals.

1. Introduction

The association between alcohol consumption and health follows a J-shaped curve [1]. Moderate alcohol use is associated with better prognosis and lower all-cause death, whereas excessive intake is detrimental to human health [1]. The mechanisms underlying the protective effects of moderate alcohol consumption are under investigation and mostly involve reduced plasminogen levels and lower thrombogenicity observed in moderate drinkers vs. abstainers [1]. Some authors propose the superiority of wine, namely red wine over other alcoholic beverages and attribute such advantage to the (poly)phenolic components of red wine [2]. Even though this notion is not fully proven and is, conversely, often challenged [2], much research is being performed to elucidate the purported biochemical mechanisms through which wine (poly)phenols would afford better health, in particular by lowering cardiovascular risk. The debate on alcohol use and health is becoming heavily polarized: one party underscores a large amount of data in support of the J curve [1,3] whereas the other side dismisses such evidence and calls for total abstention [2,3]. In support of the former, researchers and the lay press often advocate the health benefits of (poly)phenol consumption via red wine intake and cite the vast amount of in vitro literature that would corroborate the hypothesis [4,5].
In this review, we take a skeptical, Pythagorean stance and we critically try to move the debate forward by pointing the readers to the many pitfalls of red wine (poly)phenol research, which we arbitrarily treat as if they were pharmacological agents.

2. Phenolic Compounds and Health

Diet and nutrition are essential to promote and maintain good health throughout life and for many years they have been known to be of crucial importance as risk factors for chronic diseases, making them essential components of prevention activities [6]. The consumption of foods derived from plant products such as wine, fruits, vegetables, nuts, cereals, legumes, spices and others integrated into the Mediterranean or the DASH diets [7], is associated with beneficial health effects and a protective role against the development and progression of diseases, such as cardiovascular disease (CVD) [8]. The ability of some plant-derived foods to reduce disease risk has been associated with the presence of non-nutrient secondary metabolites (phytochemicals) to which a wide variety of biological activities are attributed [9,10]. These metabolites have moderate potency as bioactive compounds and low bioavailability compared to drugs, but when ingested regularly and in significant amounts can have noticeable mid/long term physiological effects. Phytochemicals present in foods associated with a beneficial health effect include glucosinolates, terpenoids and a large group of phenolic compounds (anthocyanins, flavones, flavan-3-ol, stilbenes, etc.) collectively known as (poly)phenols [10,11].

3. Classification and Amounts of Wine Phenolic Compounds

Phenolic compounds have as a common characteristic in their chemical structure the presence of one or more hydroxyl groups attached to one or more aromatic or benzene rings. In general, phenolic compounds that contain more than one phenolic group are called polyphenols to distinguish them from simple phenolics. Typically, these compounds are found in a conjugate form with one or more sugar residues linked by β-glycosidic (O-glycosylated) bonds or by direct linkages of sugar to an aromatic ring carbon atom (C-glycosides) [12]. Phenolic compounds are grouped according to their chemical structure into two main categories, flavonoids and non-flavonoids, each comprising several sub-groups. In wine, sub-groups of flavonoids compounds include flavonols, flavononols (also known as dihydroflavonols), anthocyanins, flavan-3-ols, flavanones and flavones, while non-flavonoids contain hydroxycinnamic and hydroxybenzoic acids, and stilbenes (Table 1). (Poly)phenolic composition varies among different wines according to the type of grape used, vinification process used, type of yeast that participates in the fermentation, and whether grape solids are present in the maceration process [13]. For instance, in grapes, the composition in phenolic compounds is location-dependent, i.e., pulp, skin and seeds have different types and proportions of (poly)phenols); since red wines are exposed to all grape parts during the vinification process they contain more (poly)phenols than white wines, whose contents essentially originate from the pulp. In this sense, the minimum and maximum levels of total phenolic contents reported in a representative set of studies (expressed as the median (Q25–Q75) in mg of gallic acid equivalents (GAE) per liter) were 1531 (983–1898) and 3192 (2700–3624), and 210 (89–282) and 402 (347–434) for red and white wines, respectively (Table 2). The content of polyphenols in rosé wine is intermediate between red and white wines [14,15].

3.1. Flavonoids

Flavonoids have a skeleton with 15 carbon atoms and are represented in a C6-C3-C6 type system, where a benzene ring (designated as B) is joined (in most cases) to the C2 position of a γ-pyran type ring (C) included in a chromane ring (Table 1) [33]. The structure of flavonoids is shaped by different levels of hydroxylation, prenylation, alkalization or glycosylation reactions, which give rise to different sub-groups [34]. In plants, most flavonoids exist as glycosides in combination with monosaccharides such as glucose and rhamnose (most common), followed by galactose, xylose and arabinose [35].

3.2. Flavonols

Flavonols are characterized by a hydroxyl group in C3 (Table 1) and are often named 3-hydroxyflavones. These compounds are known to play a wide range of biological activities and are considered the main active compounds within the flavonoids group [36,37]. Flavonols and their glycosides are present in red and in white wines, influencing their color, taste, and health properties [38]. Flavonols in red wine include aglycons such as myricetin, quercetin, kaempferol, and rutin and their respective glycosides (glucosides, glucuronides, galactosides and diglycosides). Quercetin 3-O-glucoside is the most representative flavonol in wines [39]. Flavonol levels in red wine can reach over 150 mg/L (Table 3).

3.3. Flavan-3-Ols

Flavanols or flavan-3-ols are responsible for the astringency, bitterness, and structure of wines, and are found in important concentrations in red wine [40]. They are benzopyrans, having no double bond between C2 and C3, and no C4 carbonyl in Ring C. Furthermore, due to the hydroxylation at C3 flavanols have two chiral centers. (+)-Catechin (trans configuration) and (−)-epicatechin (cis configuration) are the two main flavan-3-ol isomers found in red wine, with average combined concentration over 100 mg/L (Table 3). Catechins usually occur as aglycones, or esterified with gallic acid, and can form polymers, which are often referred to as proanthocyanidins (or condensed tannins) because an acid-catalyzed cleavage of the polymeric chains produces anthocyanidins. Proanthocyanidins, which present an average concentration over 350 mg/L in red wine, include, for example, procyanidin dimers B1, B2, B3 and B4. Trimers such as procyanidin C1 (three epicatechins) have also been identified.

4. Anthocyanins

Anthocyanic pigments (anthocyanidins and anthocyanins) have a structure based on the flavylium cation (2-phenylbenzopyrylium). In fact, anthocyanins are anthocyanidin glycosides, being the corresponding aglycons (anthocyanidins) obtained by hydrolysis. The great variety of anthocyanins found in nature (more than 500 anthocyanins have been described) is characterized by the different hydroxylated groups, conjugated sugars and acyl moieties they present [41,42]. The main anthocyanidins found in red wine are malvidin (most abundant), petunidin, peonidin, delphinidin and cyanidin. Often anthocyanins are found linked (mainly in position 3) to one or more sugar molecules, usually glucose, and also to acyl substituents bound to sugars, aliphatic acids, and cinnamic acids. Anthocyanins can be present in amounts higher than 700 mg/L in red wine, whereas in white wine they are essentially absent (Table 3).

4.1. Flavanones

Flavanones, also known as dihydroflavones, lack the double bond between carbons 2 and 3 in the C-ring of the flavonoid skeleton. Some flavanones have unique substitution patterns, e.g., prenylated flavanones, furanoflavanones, pyranoflavanones, benzylated flavanones, resulting in a large number of derivatives of this subgroup. One of the main flavonones found in wine is naringenin at levels that can reach 25 mg/kg (Table 3).

4.2. Flavones

Flavones are characterized by absence of a hydroxyl group in the C3 position and a conjugated double bond between C2 and C3 in the flavonoid skeleton. Flavones and their 3-hydroxy derivatives flavonols, including their glycosides, methoxides and other acylated products on all three rings, make this the largest subgroup among all polyphenols. These compounds were found in grape skin and wine in both aglycones and glycosides forms. Apigenin, for example, has been described in red wine only in trace amounts (Table 3).

5. Non-Flavonoids

The non-flavonoid phenolic constituents in wine are divided into hydroxybenzoic acids and hydroxycinnamic acids, stilbenes and other miscellaneous compounds [43]. These phenolic compounds can reach levels that range from 60 to 566 mg/L [44].

6. Hydroxycinnamic Acids

Hydroxycinnamic acids are the foremost group of phenolic compounds in grapes and wine [45]. Caffeic, coumaric, and ferulic acids, essentially conjugated with tartaric acid esters or diesters, are some of the most important compounds in this polyphenol sub-class. For instance, caftaric acid, which is composed of caffeic acid esterified with tartaric acid, is found in the pulp and represents up to 50% of total hydroxycinnamic acids [43,46]. The average amount of hydroxycinnamic acids present in red wine is around 100 and 30 mg/L in red and white wines, respectively (Table 3).

7. Hydroxybenzoic Acids

In comparison with cinnamic acid derivatives, benzoates are present at lower levels in wine (Table 3). Hydroxybenzoic acids are phenolic metabolites with a general C6–C1 structure and occur mainly in their free forms in wine, mainly as p-hydroxybenzoic, gallic, vanillic, gentisic, syringic, salicylic, and protocatechuic acids [43], although ethyl and mehyl esters of these phenolic acids have been also identified [47]. Gallic acid, which is present in important levels in white and, especially, in red wine, is the precursor of all hydrolyzable tannins and is incorporated in condensed tannins [46].

8. Stilbenes

Stilbenes are widely distributed molecules in the Plant Kingdom. However, their presence in the diet is not very significant, being basically restricted to grapes, red wine and, to a lesser extent, peanuts and blueberries [48]. Chemically they are 1,2-diarilethenes and usually have two hydroxyl groups in the meta position of ring A, while ring B is substituted with hydroxyl groups and methoxyl groups in the meta and/or para positions (Table 1). Although its concentration in wine is much lower than other polyphenols, i.e., often traces, resveratrol has received much attention for its biological properties and potential therapeutic effects (see below). The levels of resveratrol aglycone, its piceid glycoside, and its dimeric and trimeric forms (e.g., pallidol, viniferins) combined may range from negligible up to more than 100 mg/L (Table 3) when grapes are exposed to fungi.

9. Effects on Human Health

The Greek philosopher Pythagoras of Samos allegedly used to say “All is number” or “God is number” [49]. He meant that he only believed in what could be measured. This was echoed by William Thomson, 1st Baron Kelvin who, in his Popular Lectures and Addresses vol. 1 (1889) ‘Electrical Units of Measurement’, delivered 3 May 1883 notoriously said “When you can measure what you are speaking about, and express it in numbers, you know something about it, when you cannot express it in numbers, your knowledge is of a meager and unsatisfactory kind; it may be the beginning of knowledge, but you have scarcely, in your thoughts advanced to the stage of science.” [50]. What both scientists meant was that we should base our knowledge on hard evidence. More recently, Dr. Archie L. Cochrane set out clearly the vital importance of randomized controlled trials (RCTs) in assessing the effectiveness of treatments [51]. How does this apply to wine (poly)phenols?
We shall start by mentioning that there are thousands of papers published on this topic (a cursory PubMed search ran on August 14th, 2020 retrieved 2954 entries just by entering “wine polyphenols”). The near totality of such studies has been performed in vitro. Needless to say, in vitro studies are indispensable to address mechanisms of action and to propose new avenues of in vivo research. The case of wine (poly)phenols, however, is rather unique and presents us with a paradigmatic opportunity to underscore the current very limits of (poly)phenol research.
In keeping with the above, we would like to discuss the case of resveratrol as an example of molecules for which there exists a strong dyscrasia between the lay public perception of health benefits and hard scientific data.
Resveratrol became popular in 1991, when Drs. Michel de Lorgeril and Serge Renaud appeared in the “60 Minutes” CBS show to talk about the French Paradox and to attribute it to the French habit of drinking red wine, which would theoretically inhibit lipid peroxidation. Note that, back then the “free radical/antioxidant hypothesis” [52] was in full swing and it was commonplace to believe that eating and drinking (poly)phenols would scavenge free radicals and prevent their noxious effects, for example by inhibiting LDL oxidation [53]. This conjecture, now largely proven wrong [54], granted red wine (poly)phenols, namely resveratrol, immediate popularity and trigger the vast amount of well-funded research mentioned above.
Two major issues developed during the nearly three decades that separate the 60 min show from our current knowledge.
The first problem is that we came to realize that (poly)phenols are very weak (if at all effective) in vivo direct antioxidants [55]. For kinetic reasons they do not scavenge free radicals and their bioavailability is generally so low that they contribute very little to the integrated cellular antioxidant machinery, which is mostly composed of enzymes [56,57,58]. Alas, plenty of investigators still perform research and publish papers on the in vitro antioxidant abilities of individual (poly)phenols or of some raw mixtures of them. Luckily, plenty of researchers correctly use (poly)phenols’ metabolites in their in vitro studies [59,60]. The hurdle then becomes the difficulty of synthesizing such metabolites, which are often produced by the organism in different forms. It is worth underscoring that we are making progress in the identification of metabolites, but—until recently—we mainly focused on the liver-derived ones [61]. The relatively recent discovery of microbiota-synthesized metabolites amplifies the list of potential biologically-active molecules produced by the body after the ingestion of (poly)phenol-rich foods [58,62,63].
In consonance with the above, the lay press often overlooks the bioavailability issue. As regards resveratrol, already in 1993 Soleas and Goldberg acted as the harbinger of the subsequent in vivo debacle of the molecule by calling it “a molecule whose time has come and gone” [64]. That conclusive title might have been a bit too harsh, but it’s a fact that many years of research and many million dollars invested in it did not yield major results [65,66].
Finally, animal studies often employ very high doses of grape (poly)phenols, e.g., resveratrol and their results cannot be readily transferred to humans, who would need to ingest several grams of extracts to replicate the same effects. Indeed, a discrepancy between animal and human effects has just been underscored [5] and resveratrol’s potential toxicity has been recently reviewed [67]. An often overlooked paper reported that resveratrol promoted atherosclerotic development in hypercholesterolemic rabbits, by a mechanism that is independent of observed differences in gross animal health, liver function, plasma cholesterol concentrations, or LDL oxidative status [68].

10. Human Studies of Resveratrol and Red Wine (Poly)Phenols

One of the fields where red wine (poly)phenols are most actively studied is that of weight control, namely obesity and its associated insulin sensitivity [69]. The rationale behind studying red wine (poly)phenols and, particularly, resveratrol is that type II diabetes is rampant in developed countries and that many researchers are looking for fasting mimetics, to approximate the beneficial effects of calorie restriction or intermittent fasting on insulin sensitivity [70]. The results are equivocal, to say the least, as most trials failed to report significant effects, e.g., [71]. The molecular rationale for studying it is the finding that resveratrol and, maybe, other wine (poly)phenols activate SIRT1, a modulator of pathways downstream of calorie restriction that produces beneficial effects on glucose homeostasis and insulin sensitivity [72,73]. This hypothesis is quite controversial for at least two reasons. One is the factual role of sirtuins as longevity promoters [74]. The other one is that several researchers question the reproducibility of those data, e.g., [75]. In summary, the jury is still out [76] and the quixotic search for a substance that would fix the cardiometabolic effects of inordinate diets is not over [77].
Rather than trying to single out individual molecules purportedly responsible for the beneficial effects of moderate wine use (which is a pharmacological approach), an alternative is to test the effects of the whole (poly)phenolic fraction. We retrieved 24 publications of human studies that employed dealcoholized wine (Table S1). Taken together, their results indicate that wine (poly)phenols do exert healthful effects, ranging from anti-inflammatory actions to modulation of the microbiota, which is now gaining traction from an industrial viewpoint [78,79] and might be one of the next applications of these compounds. The extent and precise nature of such activities, however, remains to be fully elucidated. For example, some publications stem from the same study; there are some contradictions between data and their discussion (e.g., LPS and LPB data in [80], fatty acid data in [81], inflammatory markers in [82], etc.); and the true clinical relevance of microbiota modification as related to, e.g., circulating lipids (Table S1) [83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106]. In summary, there is indeed evidence that wine (poly)phenols modulate human physiology, but puffery should be avoided until we can clearly correlate such modifications with undisputable clinical outcomes.
We also searched the literature for acute or short-term human effects of wine (poly)phenols (Table S2) [107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123]. Even though this might be seen as a more classic “pharmacological” approach, even small effects repeated over time might—in the end—affect human physiology and health. Some outcomes fall in the now-outdated “plasma antioxidant capacity” or “oxLDL” areas, i.e., are poor proxies of prognosis. Other data are more physiologically relevant and indicate, e.g., salubrious effects on endothelial function and related flow-mediated dilation. Anti-inflammatory effects have also been reported. Other studies focused on bioavailability, with scant indications of biological effects. It is worth noting that ethical reasons often impede research on alcohol in humans [1].

11. Wine vs. Other Alcoholic Beverages: Does Digestion Make the Difference?

Often miscategorized as direct antioxidants [124] (see above) wine (poly)phenols might act as such during digestion. Several pieces of evidence reveal that, during digestion, lipid peroxides are formed in the stomach at millimolar concentrations [125]. In addition, we eat pre-formed hydroperoxides, whose formation is unavoidable in fat-containing foods. Dr. Kanner called the stomach “a bioreactor” [125] where hydroperoxides are formed and subsequently absorbed. This is particularly noteworthy in the case of red meat (hypothetically because of its iron content [126]), but it is likely to happen with any animal food. Lipid peroxidation during digestion can be decreased by the consumption of (poly)phenol rich foods and beverages such as extra virgin olive oil [127] and—germane to this review—red wine [128,129]. In a wider context, these data experimentally explain the evolutionary-sound habit of eating fruit and vegetables, i.e., (poly)phenols with protein [130]. Further, most cultures have culinary routines that involve drinking (poly)phenols during or after meals, including tea [131], coffee [132,133], red wine [128], etc.
Another place where wine (poly)phenols might act as indirect antioxidants is the liver, where ethanol is metabolized to acetaldehyde by the microsomal ethanol oxidizing system (MEOS), via cyp2E1 [134]. In doing, ROS are generated as by-products. Possibly, (poly)phenols might lessen this untoward effect of ethanol ingestion, through mechanisms that are yet to be elucidated.

12. Conclusions

In this review, we took a pharma-nutritional approach to wine (poly)phenols. Epidemiological evidence describes the association between alcohol use and all-cause mortality as following a J-shaped curve. Many investigators claim the superiority of wine, namely red wine with respect to other alcoholic beverages and call for (poly)phenols to support their hypothesis. The result is that the lay public often believes in this premise, in part because there is plenty of in vitro and some animal data and in part due to wish bias [135]. Indeed, there appears to be a discrepancy between the strength of biochemical data and the scantiness of well-controlled human trials of individual molecules isolated from wine. This is commonplace in nutritional research [136,137] and there is no easy way out of it [138]. In a way, wine (poly)phenols are paradigmatic of the current tension between treating such compounds as non-essential nutritional agents and expecting pharmacological actions from them [139]. In the former case, we must accept the fact that the biological effects of wine (poly)phenols are minimal and very difficult to detect with current technologies and biomarkers [138,139]. The latter scenario involves the unavoidable acceptance of side effects and is not epistemologically applicable to human nutrition. Another limitation of wine (poly)phenol research is that we often use a reductionist approach and look for one single mechanism of action. In the case of wine (poly)phenols and particularly resveratrol, this involves their misclassification as in vivo free radical scavengers and antioxidants, even if their mechanisms of action are manifold and chiefly involve anti-inflammatory actions and, possibly, activation of nrf2 and its downstream pathways via xeno-hormesis [1]. In pharma-nutritional research we should look at a wider picture and acknowledge that phytochemicals contribute to health even though, based on the definition of nutrients, they are not essential. Therefore, these molecules do not fit in the classic and rigorous pharmacological definitions; they can be modified by organisms before they interact with targets, can have different targets depending on their concentration, and do not have a univocal pharmacological mechanism of action.
In conclusion, after 30 years of dedicated research and despite the considerable expenditure, we still lack solid, “pharmacological” human evidence to confirm wine (poly)phenols’ biological actions (Figure 1). Future research [138] will eventually clarify their activities and will back the current recommendations of responsibly drinking moderate amounts of wine with meals.

Supplementary Materials

The following are available online, Table S1: Human long-term studies with dealcoholized red wine, Table S2: Human acute or short-term studies with dealcoholized red wine.

Author Contributions

This is an Invited Review and all authors (F.V., S.-A.P., and J.T.-C.) contributed to drafting, revising, and finalizing it. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Acknowledgments

This publication was not funded. We thank Paula Silva for inviting us to contribute to this Special Issue. This manuscript forms part of S-A.P. dissertation to obtain his M.D. degree.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Poli, A.; Marangoni, F.; Avogaro, A.; Barba, G.; Bellentani, S.; Bucci, M.; Cambieri, R.; Catapano, A.L.; Costanzo, S.; Cricelli, C.; et al. Moderate alcohol use and health: A consensus document. Nutr. Metab. Cardiovasc. Dis. 2013, 23, 487–504. [Google Scholar] [CrossRef] [PubMed]
  2. Holst, C.; Becker, U.; Jorgensen, M.E.; Gronbaek, M.; Tolstrup, J.S. Alcohol drinking patterns and risk of diabetes: A cohort study of 70,551 men and women from the general Danish population. Diabetologia 2017, 60, 1941–1950. [Google Scholar] [CrossRef] [PubMed]
  3. Costanzo, S.; de Gaetano, G.; Di Castelnuovo, A.; Djousse, L.; Poli, A.; van Velden, D.P. Moderate alcohol consumption and lower total mortality risk: Justified doubts or established facts? Nutr. Metab. Cardiovasc. Dis. 2019, 29, 1003–1008. [Google Scholar] [CrossRef] [PubMed]
  4. Ditano-Vazquez, P.; Torres-Pena, J.D.; Galeano-Valle, F.; Perez-Caballero, A.I.; Demelo-Rodriguez, P.; Lopez-Miranda, J.; Katsiki, N.; Delgado-Lista, J.; Alvarez-Sala-Walther, L.A. The Fluid Aspect of the Mediterranean Diet in the Prevention and Management of Cardiovascular Disease and Diabetes: The Role of Polyphenol Content in Moderate Consumption of Wine and Olive Oil. Nutrients 2019, 11, 2833. [Google Scholar] [CrossRef] [Green Version]
  5. Weaver, S.R.; Rendeiro, C.; McGettrick, H.M.; Philp, A.; Lucas, S.J.E. Fine wine or sour grapes? A systematic review and meta-analysis of the impact of red wine polyphenols on vascular health. Eur. J. Nutr. 2020. [Google Scholar] [CrossRef] [Green Version]
  6. WHO. Diet, nutrition and the prevention of chronic diseases. World Health Organ. Tech. Rep. Ser. 2003, 916, 1–149. [Google Scholar]
  7. Yazdi, F.; Morreale, P.; Reisin, E. First Course DASH, Second Course Mediterranean: Comparing Renal Outcomes for Two “Heart-Healthy” Diets. Curr. Hypertens Rep. 2020, 22, 54. [Google Scholar] [CrossRef]
  8. Bhupathiraju, S.N.; Tucker, K.L. Coronary heart disease prevention: Nutrients, foods, and dietary patterns. Clin. Chim. Acta 2011, 412, 1493–1514. [Google Scholar] [CrossRef] [Green Version]
  9. Visioli, F.; Bogani, P.; Grande, S.; Detopoulou, V.; Manios, Y.; Galli, C. Local food and cardioprotection: The role of phytochemicals. Forum. Nutr. 2006, 59, 116–129. [Google Scholar] [CrossRef]
  10. Holst, B.; Williamson, G. Nutrients and phytochemicals: From bioavailability to bioefficacy beyond antioxidants. Curr. Opin. Biotechnol. 2008, 19, 73–82. [Google Scholar] [CrossRef]
  11. Barabási, A.; Menichetti, G.; Loscalzo, J. The unmapped chemical complexity of our diet. Nat. Food 2019, 1, 33–37. [Google Scholar] [CrossRef] [Green Version]
  12. Manach, C.; Scalbert, A.; Morand, C.; Remesy, C.; Jimenez, L. Polyphenols: Food sources and bioavailability. Am. J. Clin. Nutr. 2004, 79, 727–747. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Baiano, A.; Terracone, C.; Gambacorta, G.; La Notte, E. Phenolic content and antioxidant activity of Primitivo wine: Comparison among winemaking technologies. J. Food Sci. 2009, 74, C258–C267. [Google Scholar] [CrossRef] [PubMed]
  14. Li, H.; Wang, X.; Li, Y.; Li, P.; Wang, H. Polyphenolic compounds and antioxidant properties of selected China wines. Food Chem. 2009, 112, 454–460. [Google Scholar] [CrossRef]
  15. Paixão, N.; Perestrelo, R.; Marques, J.C.; Câmara, J.S. Relationship between antioxidant capacity and total phenolic content of red, rosé and white wines. Food Chem. 2007, 105, 204–214. [Google Scholar] [CrossRef] [Green Version]
  16. Minussi, R.C.; Rossi, M.; Bologna, L.; Cordi, L.v.; Rotilio, D.; Pastore, G.M.; Durán, N. Phenolic compounds and total antioxidant potential of commercial wines. Food Chem. 2003, 82, 409–416. [Google Scholar] [CrossRef]
  17. Fernández-Pachón, M.S.; Villaño, D.; García-Parrilla, M.C.; Troncoso, A.M. Antioxidant activity of wines and relation with their polyphenolic composition. Anal. Chim. Acta 2004, 513, 113–118. [Google Scholar] [CrossRef]
  18. Katalinić, V.; Milos, M.; Modun, D.; Musić, I.; Boban, M. Antioxidant effectiveness of selected wines in comparison with (+)-catechin. Food Chem. 2004, 86, 593–600. [Google Scholar] [CrossRef]
  19. Kallithraka, S.; Tsoutsouras, E.; Tzourou, E.; Lanaridis, P. Principal phenolic compounds in Greek red wines. Food Chem. 2006, 99, 784–793. [Google Scholar] [CrossRef]
  20. Di Majo, D.; La Guardia, M.; Giammanco, S.; La Neve, L.; Giammanco, M. The antioxidant capacity of red wine in relationship with its polyphenolic constituents. Food Chem. 2008, 111, 45–49. [Google Scholar] [CrossRef]
  21. Staško, A.; Brezová, V.; Mazúr, M.; Čertík, M.; Kaliňák, M.; Gescheidt, G. A comparative study on the antioxidant properties of Slovakian and Austrian wines. LWT Food Sci. Technol. 2008, 41, 2126–2135. [Google Scholar] [CrossRef]
  22. Roussis, I.G.; Lambropoulos, I.; Tzimas, P.; Gkoulioti, A.; Marinos, V.; Tsoupeis, D.; Boutaris, I. Antioxidant activities of some Greek wines and wine phenolic extracts. J. Food Compos. Anal. 2008, 21, 614–621. [Google Scholar] [CrossRef]
  23. Lucena, A.P.S.; Nascimento, R.J.B.; Maciel, J.A.C.; Tavares, J.X.; Barbosa-Filho, J.M.; Oliveira, E.J. Antioxidant activity and phenolics content of selected Brazilian wines. J. Food Compos. Anal. 2010, 23, 30–36. [Google Scholar] [CrossRef]
  24. Jordão, A.M.; Gonçalves Fj Fau-Correia, A.C.; Correia Ac Fau-Cantão, J.; Cantão J Fau-Rivero-Pérez, M.D.; Rivero-Pérez Md Fau-González Sanjosé, M.L.; González Sanjosé, M.L. Proanthocyanidin content, antioxidant capacity and scavenger activity of Portuguese sparkling wines (Bairrada Appellation of Origin). J. Sci. Food Agric. 2010, 90, 2144–2152. [Google Scholar] [CrossRef]
  25. Šeruga, M.; Novak, I.; Jakobek, L. Determination of polyphenols content and antioxidant activity of some red wines by differential pulse voltammetry, HPLC and spectrophotometric methods. Food Chem. 2011, 124, 1208–1216. [Google Scholar] [CrossRef]
  26. Vrček, I.V.; Bojić, M.; Žuntar, I.; Mendaš, G.; Medić-Šarić, M. Phenol content, antioxidant activity and metal composition of Croatian wines deriving from organically and conventionally grown grapes. Food Chem. 2011, 124, 354–361. [Google Scholar] [CrossRef]
  27. Yoo, Y.J.; Prenzler Pd Fau-Saliba, A.J.; Saliba Aj Fau-Ryan, D.; Ryan, D. Assessment of some Australian red wines for price, phenolic content, antioxidant activity, and vintage in relation to functional food prospects. J. Food Sci. 2011, 76, C1355–C1364. [Google Scholar] [CrossRef]
  28. Ružić, I.; Škerget, M.; Knez, Ž.; Runje, M. Phenolic content and antioxidant potential of macerated white wines. Eur. Food Res. Technol. 2011, 233, 465. [Google Scholar] [CrossRef]
  29. Jiang, B.; Zhang, Z.W. Comparison on phenolic compounds and antioxidant properties of cabernet sauvignon and merlot wines from four wine grape-growing regions in China. Molecules 2012, 17, 8804–8821. [Google Scholar] [CrossRef] [Green Version]
  30. Radovanović, A.N.; Jovančićević Bs Fau-Radovanović, B.C.; Radovanović Bc Fau-Mihajilov-Krstev, T.; Mihajilov-Krstev, T.; Fau-Zvezdanović, J.B.; Zvezdanović, J.B. Antioxidant and antimicrobial potentials of Serbian red wines produced from international Vitis vinifera grape varieties. J. Sci. Food Agric. 2012, 92, 2154–2161. [Google Scholar] [CrossRef]
  31. Porgalı, E.; Büyüktuncel, E. Determination of phenolic composition and antioxidant capacity of native red wines by high performance liquid chromatography and spectrophotometric methods. Food Res. Int. 2012, 45, 145–154. [Google Scholar] [CrossRef]
  32. Agatonovic-Kustrin, S.; Hettiarachchi, C.G.; Morton, D.W.; Razic, S. Analysis of phenolics in wine by high performance thin-layer chromatography with gradient elution and high resolution plate imaging. J. Pharm. Biomed. Anal. 2015, 102, 93–99. [Google Scholar] [CrossRef] [PubMed]
  33. Ferrazzano, G.F.; Amato, I.; Ingenito, A.; Zarrelli, A.; Pinto, G.; Pollio, A. Plant polyphenols and their anti-cariogenic properties: A review. Molecules 2011, 16, 1486–1507. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Stalikas, C.D. Extraction, separation, and detection methods for phenolic acids and flavonoids. J. Sep. Sci. 2007, 30, 3268–3295. [Google Scholar] [CrossRef]
  35. Yang, B.; Liu, H.; Yang, J.; Gupta, V.K.; Jiang, Y. New insights on bioactivities and biosynthesis of flavonoid glycosides. Trends Food Sci. Technol. 2018, 79, 116–124. [Google Scholar] [CrossRef]
  36. Perez-Vizcaino, F.; Duarte, J. Flavonols and cardiovascular disease. Mol. Aspects Med. 2010, 31, 478–494. [Google Scholar] [CrossRef]
  37. Ku, Y.S.; Ng, M.S.; Cheng, S.S.; Lo, A.W.; Xiao, Z.; Shin, T.S.; Chung, G.; Lam, H.M. Understanding the Composition, Biosynthesis, Accumulation and Transport of Flavonoids in Crops for the Promotion of Crops as Healthy Sources of Flavonoids for Human Consumption. Nutrients 2020, 12, 1717. [Google Scholar] [CrossRef]
  38. Jeffery, D.W.; Parker, M.; Smith, P.A. Flavonol composition of Australian red and white wines determined by high-performance liquid chromatography. Aust. J. Grape Wine Res. 2008, 14, 153–161. [Google Scholar] [CrossRef]
  39. Cueva, C.; Gil-Sanchez, I.; Ayuda-Duran, B.; Gonzalez-Manzano, S.; Gonzalez-Paramas, A.M.; Santos-Buelga, C.; Bartolome, B.; Moreno-Arribas, M.V. An Integrated View of the Effects of Wine Polyphenols and Their Relevant Metabolites on Gut and Host Health. Molecules 2017, 22, 99. [Google Scholar] [CrossRef]
  40. Li, S.Y.; Duan, C.Q. Astringency, bitterness and color changes in dry red wines before and during oak barrel aging: An updated phenolic perspective review. Crit. Rev. Food Sci. Nutr. 2019, 59, 1840–1867. [Google Scholar] [CrossRef] [PubMed]
  41. Tsao, R. Chemistry and biochemistry of dietary polyphenols. Nutrients 2010, 2, 1231–1246. [Google Scholar] [CrossRef] [PubMed]
  42. Sanchez-Ilarduya, M.B.; Sanchez-Fernandez, C.; Garmon-Lobato, S.; Abad-Garcia, B.; Berrueta, L.A.; Gallo, B.; Vicente, F. Detection of non-coloured anthocyanin-flavanol derivatives in Rioja aged red wines by liquid chromatography-mass spectrometry. Talanta 2014, 121, 81–88. [Google Scholar] [CrossRef]
  43. Rentzsch, M.; Wilkens, A.; Winterhalter, P. Non-flavonoid Phenolic Compounds. In Wine Chemistry and Biochemistry; Moreno-Arribas, M.V., Polo, M.C., Eds.; Springer: New York, NY, USA, 2009; pp. 509–527. [Google Scholar] [CrossRef]
  44. Castaldo, L.; Narvaez, A.; Izzo, L.; Graziani, G.; Gaspari, A.; Minno, G.D.; Ritieni, A. Red Wine Consumption and Cardiovascular Health. Molecules 2019, 24, 3626. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Ferreira-Lima, N.; Vallverdu-Queralt, A.; Meudec, E.; Pinasseau, L.; Verbaere, A.; Bordignon-Luiz, M.T.; Le Guerneve, C.; Cheynier, V.; Sommerer, N. Quantification of hydroxycinnamic derivatives in wines by UHPLC-MRM-MS. Anal. Bioanal. Chem. 2018, 410, 3483–3490. [Google Scholar] [CrossRef] [PubMed]
  46. Garrido, J.; Borges, F. Wine and grape polyphenols—A chemical perspective. Food Res. Int. 2013, 54, 1844–1858. [Google Scholar] [CrossRef] [Green Version]
  47. Baderschneider, B.; Winterhalter, P. Isolation and characterization of novel benzoates, cinnamates, flavonoids, and lignans from Riesling wine and screening for antioxidant activity. J. Agric. Food Chem. 2001, 49, 2788–2798. [Google Scholar] [CrossRef] [PubMed]
  48. Neveu, V.; Perez-Jimenez, J.; Vos, F.; Crespy, V.; du Chaffaut, L.; Mennen, L.; Knox, C.; Eisner, R.; Cruz, J.; Wishart, D.; et al. Phenol-Explorer: An online comprehensive database on polyphenol contents in foods. Database (Oxford) 2010, 2010, bap024. [Google Scholar] [CrossRef] [PubMed]
  49. Kahn, C.H. Pythagoras and the Pythagoreans: A Brief History; Hackett Pub Co Inc.: Indianapolis, IN, USA, 2001. [Google Scholar]
  50. Ratcliffe, S. Oxford Essential Quotation, 4th ed.; Oxford University Press: Oxford, UK, 2016. [Google Scholar]
  51. Cochrane, A.L. Effectiveness and Efficiency: Random Reflections on Health Services; Nuffield Trust: New York, NY, USA, 1972. [Google Scholar]
  52. Koltover, V.K. Free Radical Timer of Aging: From Chemistry of Free Radicals to Systems Theory of Reliability. Curr. Aging Sci. 2017, 10, 12–17. [Google Scholar] [CrossRef] [PubMed]
  53. Frankel, E.N.; Kanner, J.; German, J.B.; Parks, E.; Kinsella, J.E. Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wine. Lancet 1993, 341, 454–457. [Google Scholar] [CrossRef]
  54. Visioli, F.; Keaney, J.F.; Halliwell, B. Antioxidants and cardiovascular disease; panaceas or tonics for tired sheep? Cardiovasc. Res. 2000, 47, 409. [Google Scholar] [CrossRef] [Green Version]
  55. Forman, H.J.; Davies, K.J.; Ursini, F. How do nutritional antioxidants really work: Nucleophilic tone and para-hormesis versus free radical scavenging in vivo. Free Radic. Biol. Med. 2014, 66, 24–35. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  56. Lotito, S.B.; Frei, B. Consumption of flavonoid-rich foods and increased plasma antioxidant capacity in humans: Cause, consequence, or epiphenomenon? Free Radic. Biol. Med. 2006, 41, 1727–1746. [Google Scholar] [CrossRef]
  57. Sies, H. Polyphenols and health: Update and perspectives. Arch. Biochem. Biophys. 2010, 501, 2–5. [Google Scholar] [CrossRef] [PubMed]
  58. Visioli, F.; De La Lastra, C.A.; Andres-Lacueva, C.; Aviram, M.; Calhau, C.; Cassano, A.; D’Archivio, M.; Faria, A.; Fave, G.; Fogliano, V.; et al. Polyphenols and human health: A prospectus. Crit. Rev. Food Sci. Nutr. 2011, 51, 524–546. [Google Scholar] [CrossRef] [PubMed]
  59. Rodriguez-Mateos, A.; Vauzour, D.; Krueger, C.G.; Shanmuganayagam, D.; Reed, J.; Calani, L.; Mena, P.; Del Rio, D.; Crozier, A. Bioavailability, bioactivity and impact on health of dietary flavonoids and related compounds: An update. Arch. Toxicol. 2014, 88, 1803–1853. [Google Scholar] [CrossRef]
  60. Tome-Carneiro, J.; Visioli, F. Polyphenol-based nutraceuticals for the prevention and treatment of cardiovascular disease: Review of human evidence. Phytomedicine 2016, 23, 1145–1174. [Google Scholar] [CrossRef]
  61. Castellano-Escuder, P.; Gonzalez-Dominguez, R.; Wishart, D.S.; Andres-Lacueva, C.; Sanchez-Pla, A. FOBI: An ontology to represent food intake data and associate it with metabolomic data. Database (Oxford) 2020, 2020. [Google Scholar] [CrossRef]
  62. Gonzalez-Dominguez, R.; Jauregui, O.; Mena, P.; Hanhineva, K.; Tinahones, F.J.; Angelino, D.; Andres-Lacueva, C. Quantifying the human diet in the crosstalk between nutrition and health by multi-targeted metabolomics of food and microbiota-derived metabolites. Int. J. Obes. (Lond.) 2020. [Google Scholar] [CrossRef]
  63. Scarmozzino, F.; Poli, A.; Visioli, F. Microbiota and cardiovascular disease risk: A scoping review. Pharmacol. Res. 2020, 159, 104952. [Google Scholar] [CrossRef]
  64. Soleas, G.J.; Diamandis, E.P.; Goldberg, D.M. Resveratrol: A molecule whose time has come? And gone? Clin. Biochem. 1997, 30, 91–113. [Google Scholar] [CrossRef]
  65. Visioli, F. The resveratrol fiasco. Pharmacol. Res. 2014, 90, 87. [Google Scholar] [CrossRef] [PubMed]
  66. Tang, P.C.; Ng, Y.F.; Ho, S.; Gyda, M.; Chan, S.W. Resveratrol and cardiovascular health--promising therapeutic or hopeless illusion? Pharmacol. Res. 2014, 90, 88–115. [Google Scholar] [CrossRef] [PubMed]
  67. Shaito, A.; Posadino, A.M.; Younes, N.; Hasan, H.; Halabi, S.; Alhababi, D.; Al-Mohannadi, A.; Abdel-Rahman, W.M.; Eid, A.H.; Nasrallah, G.K.; et al. Potential Adverse Effects of Resveratrol: A Literature Review. Int. J. Mol. Sci. 2020, 21, 2084. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  68. Wilson, T.; Knight, T.J.; Beitz, D.C.; Lewis, D.S.; Engen, R.L. Resveratrol promotes atherosclerosis in hypercholesterolemic rabbits. Life Sci. 1996, 59, PL15–PL21. [Google Scholar] [CrossRef]
  69. Woerdeman, J.; Del Rio, D.; Calani, L.; Eringa, E.C.; Smulders, Y.M.; Serne, E.H. Red wine polyphenols do not improve obesity-associated insulin resistance: A randomized controlled trial. Diabetes Obes. Metab. 2018, 20, 206–210. [Google Scholar] [CrossRef]
  70. Most, J.; Tosti, V.; Redman, L.M.; Fontana, L. Calorie restriction in humans: An update. Ageing Res. Rev. 2017, 39, 36–45. [Google Scholar] [CrossRef]
  71. Bo, S.; Ponzo, V.; Ciccone, G.; Evangelista, A.; Saba, F.; Goitre, I.; Procopio, M.; Pagano, G.F.; Cassader, M.; Gambino, R. Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial. Pharmacol. Res. 2016, 111, 896–905. [Google Scholar] [CrossRef]
  72. Milne, J.C.; Lambert, P.D.; Schenk, S.; Carney, D.P.; Smith, J.J.; Gagne, D.J.; Jin, L.; Boss, O.; Perni, R.B.; Vu, C.B.; et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007, 450, 712–716. [Google Scholar] [CrossRef] [Green Version]
  73. Kaeberlein, M.; McDonagh, T.; Heltweg, B.; Hixon, J.; Westman, E.A.; Caldwell, S.D.; Napper, A.; Curtis, R.; DiStefano, P.S.; Fields, S.; et al. Substrate-specific activation of sirtuins by resveratrol. J. Biol. Chem. 2005, 280, 17038–17045. [Google Scholar] [CrossRef] [Green Version]
  74. Dang, W. The controversial world of sirtuins. Drug Discov. Today Technol. 2014, 12, e9–e17. [Google Scholar] [CrossRef] [Green Version]
  75. Pacholec, M.; Bleasdale, J.E.; Chrunyk, B.; Cunningham, D.; Flynn, D.; Garofalo, R.S.; Griffith, D.; Griffor, M.; Loulakis, P.; Pabst, B.; et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J. Biol. Chem. 2010, 285, 8340–8351. [Google Scholar] [CrossRef] [Green Version]
  76. Yuan, H.; Marmorstein, R. Biochemistry. Red wine, toast of the town (again). Science 2013, 339, 1156–1157. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  77. Gliemann, L. Dodging physical activity and healthy diet: Can resveratrol take the edge off the consequences of your lifestyle? Am. J. Clin. Nutr. 2020. [Google Scholar] [CrossRef] [PubMed]
  78. Van de Burgwal, L.H.M.; van der Waal, M.B.; Claassen, E. Accelerating microbiota product development: The Societal Impact Value Cycle as a conceptual model to shape and improve public-private valorization processes. PharmaNutrition 2018, 6, 157–168. [Google Scholar] [CrossRef]
  79. Flach, J.; dos Ribeiro, C.S.; van der Waal, M.B.; van der Waal, R.X.; Claassen, E.; Van de Burgwal, L.H.M. The Nagoya Protocol on Access to Genetic Resources and Benefit Sharing: Best practices for users of Lactic Acid Bacteria. PharmaNutrition 2019, 9, 100158. [Google Scholar] [CrossRef]
  80. Clemente-Postigo, M.; Queipo-Ortuno, M.I.; Boto-Ordonez, M.; Coin-Araguez, L.; Roca-Rodriguez, M.M.; Delgado-Lista, J.; Cardona, F.; Andres-Lacueva, C.; Tinahones, F.J. Effect of acute and chronic red wine consumption on lipopolysaccharide concentrations. Am. J. Clin. Nutr. 2013, 97, 1053–1061. [Google Scholar] [CrossRef] [Green Version]
  81. Banini, A.E.; Boyd, L.C.; Allen, J.C.; Allen, H.G.; Sauls, D.L. Muscadine grape products intake, diet and blood constituents of non-diabetic and type 2 diabetic subjects. Nutrition 2006, 22, 1137–1145. [Google Scholar] [CrossRef]
  82. Chiva-Blanch, G.; Urpi-Sarda, M.; Llorach, R.; Rotches-Ribalta, M.; Guillen, M.; Casas, R.; Arranz, S.; Valderas-Martinez, P.; Portoles, O.; Corella, D.; et al. Differential effects of polyphenols and alcohol of red wine on the expression of adhesion molecules and inflammatory cytokines related to atherosclerosis: A randomized clinical trial. Am. J. Clin. Nutr. 2012, 95, 326–334. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  83. Queipo-Ortuno, M.I.; Boto-Ordonez, M.; Murri, M.; Gomez-Zumaquero, J.M.; Clemente-Postigo, M.; Estruch, R.; Cardona Diaz, F.; Andres-Lacueva, C.; Tinahones, F.J. Influence of red wine polyphenols and ethanol on the gut microbiota ecology and biochemical biomarkers. Am. J. Clin. Nutr. 2012, 95, 1323–1334. [Google Scholar] [CrossRef]
  84. Barden, A.; Shinde, S.; Phillips, M.; Beilin, L.; Mas, E.; Hodgson, J.M.; Puddey, I.; Mori, T.A. The effects of alcohol on plasma lipid mediators of inflammation resolution in patients with Type 2 diabetes mellitus. Prostaglandins Leukot Essent. Fat. Acids 2018, 133, 29–34. [Google Scholar] [CrossRef] [Green Version]
  85. Barden, A.E.; Chavez, V.; Phillips, M.; Mas, E.; Beilin, L.J.; Croft, K.D.; Mori, T.A.; Puddey, I.B. A Randomized Trial of Effects of Alcohol on Cytochrome P450 Eicosanoids, Mediators of Inflammation Resolution, and Blood Pressure in Men. Alcohol. Clin. Exp. Res. 2017, 41, 1666–1674. [Google Scholar] [CrossRef]
  86. Mori, T.A.; Burke, V.; Zilkens, R.R.; Hodgson, J.M.; Beilin, L.J.; Puddey, I.B. The effects of alcohol on ambulatory blood pressure and other cardiovascular risk factors in type 2 diabetes: A randomized intervention. J. Hypertens 2016, 34, 421–428. [Google Scholar] [CrossRef] [PubMed]
  87. Moreno-Indias, I.; Sanchez-Alcoholado, L.; Perez-Martinez, P.; Andres-Lacueva, C.; Cardona, F.; Tinahones, F.; Queipo-Ortuno, M.I. Red wine polyphenols modulate fecal microbiota and reduce markers of the metabolic syndrome in obese patients. Food Funct. 2016, 7, 1775–1787. [Google Scholar] [CrossRef] [Green Version]
  88. Mori, T.A.; Burke, V.; Beilin, L.J.; Puddey, I.B. Randomized Controlled Intervention of the Effects of Alcohol on Blood Pressure in Premenopausal Women. Hypertension 2015, 66, 517–523. [Google Scholar] [CrossRef]
  89. Boto-Ordonez, M.; Urpi-Sarda, M.; Queipo-Ortuno, M.I.; Tulipani, S.; Tinahones, F.J.; Andres-Lacueva, C. High levels of Bifidobacteria are associated with increased levels of anthocyanin microbial metabolites: A randomized clinical trial. Food Funct. 2014, 5, 1932–1938. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  90. Jimenez-Giron, A.; Queipo-Ortuno, M.I.; Boto-Ordonez, M.; Munoz-Gonzalez, I.; Sanchez-Patan, F.; Monagas, M.; Martin-Alvarez, P.J.; Murri, M.; Tinahones, F.J.; Andres-Lacueva, C.; et al. Comparative study of microbial-derived phenolic metabolites in human feces after intake of gin, red wine, and dealcoholized red wine. J. Agric. Food Chem. 2013, 61, 3909–3915. [Google Scholar] [CrossRef] [PubMed]
  91. Chiva-Blanch, G.; Urpi-Sarda, M.; Ros, E.; Valderas-Martinez, P.; Casas, R.; Arranz, S.; Guillen, M.; Lamuela-Raventos, R.M.; Llorach, R.; Andres-Lacueva, C.; et al. Effects of red wine polyphenols and alcohol on glucose metabolism and the lipid profile: A randomized clinical trial. Clin. Nutr. 2013, 32, 200–206. [Google Scholar] [CrossRef] [PubMed]
  92. Chiva-Blanch, G.; Urpi-Sarda, M.; Ros, E.; Arranz, S.; Valderas-Martinez, P.; Casas, R.; Sacanella, E.; Llorach, R.; Lamuela-Raventos, R.M.; Andres-Lacueva, C.; et al. Dealcoholized red wine decreases systolic and diastolic blood pressure and increases plasma nitric oxide: Short communication. Circ. Res. 2012, 111, 1065–1068. [Google Scholar] [CrossRef] [Green Version]
  93. Vazquez-Fresno, R.; Llorach, R.; Alcaro, F.; Rodriguez, M.A.; Vinaixa, M.; Chiva-Blanch, G.; Estruch, R.; Correig, X.; Andres-Lacueva, C. (1)H-NMR-based metabolomic analysis of the effect of moderate wine consumption on subjects with cardiovascular risk factors. Electrophoresis 2012, 33, 2345–2354. [Google Scholar] [CrossRef] [Green Version]
  94. Schrieks, I.C.; van den Berg, R.; Sierksma, A.; Beulens, J.W.; Vaes, W.H.; Hendriks, H.F. Effect of red wine consumption on biomarkers of oxidative stress. Alcohol. Alcohol. 2013, 48, 153–159. [Google Scholar] [CrossRef] [Green Version]
  95. Noguer, M.A.; Cerezo, A.B.; Donoso Navarro, E.; Garcia-Parrilla, M.C. Intake of alcohol-free red wine modulates antioxidant enzyme activities in a human intervention study. Pharmacol. Res. 2012, 65, 609–614. [Google Scholar] [CrossRef] [PubMed]
  96. Imhof, A.; Plamper, I.; Maier, S.; Trischler, G.; Koenig, W. Effect of drinking on adiponectin in healthy men and women: A randomized intervention study of water, ethanol, red wine, and beer with or without alcohol. Diabetes Care 2009, 32, 1101–1103. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  97. Ellinger, S.; Arendt, B.M.; Fimmers, R.; Stehle, P.; Spengler, U.; Goerlich, R. Bolus ingestion but not regular consumption of native or dealcoholized red wine modulates selected immunological functions of leukocytes in healthy volunteers. Ann. Nutr. Metab. 2008, 52, 288–295. [Google Scholar] [CrossRef] [PubMed]
  98. Beulens, J.W.; van Beers, R.M.; Stolk, R.P.; Schaafsma, G.; Hendriks, H.F. The effect of moderate alcohol consumption on fat distribution and adipocytokines. Obes. (Silver Spring) 2006, 14, 60–66. [Google Scholar] [CrossRef]
  99. Arendt, B.M.; Ellinger, S.; Kekic, K.; Geus, L.; Fimmers, R.; Spengler, U.; Muller, W.U.; Goerlich, R. Single and repeated moderate consumption of native or dealcoholized red wine show different effects on antioxidant parameters in blood and DNA strand breaks in peripheral leukocytes in healthy volunteers: A randomized controlled trial (ISRCTN68505294). Nutr. J. 2005, 4, 33. [Google Scholar] [CrossRef] [Green Version]
  100. Zilkens, R.R.; Burke, V.; Hodgson, J.M.; Barden, A.; Beilin, L.J.; Puddey, I.B. Red wine and beer elevate blood pressure in normotensive men. Hypertension 2005, 45, 874–879. [Google Scholar] [CrossRef]
  101. Watzl, B.; Bub, A.; Pretzer, G.; Roser, S.; Barth, S.W.; Rechkemmer, G. Daily moderate amounts of red wine or alcohol have no effect on the immune system of healthy men. Eur. J. Clin. Nutr. 2004, 58, 40–45. [Google Scholar] [CrossRef]
  102. Abu-Amsha Caccetta, R.; Burke, V.; Mori, T.A.; Beilin, L.J.; Puddey, I.B.; Croft, K.D. Red wine polyphenols, in the absence of alcohol, reduce lipid peroxidative stress in smoking subjects. Free Radic. Biol. Med. 2001, 30, 636–642. [Google Scholar] [CrossRef]
  103. McDonald, J.T.; Margen, S. Wine versus ethanol in human nutrition. IV. Zinc balance. Am. J. Clin. Nutr. 1980, 33, 1096–1102. [Google Scholar] [CrossRef] [Green Version]
  104. McDonald, J.T.; Margen, S. Wine versus ethanol in human nutrition. III. Calcium, phosphorous, and magnesium balance. Am. J. Clin. Nutr. 1979, 32, 823–833. [Google Scholar] [CrossRef]
  105. McDonald, J.T.; Margen, S. Wine versus ethanol in human nutrition. II. Fluid, sodium, and potassium balance. Am. J. Clin. Nutr. 1979, 32, 817–822. [Google Scholar] [CrossRef]
  106. McDonald, J.T.; Margen, S. Wine versus ethanol in human nutrition. I. Nitrogen and calorie balance. Am. J. Clin. Nutr. 1976, 29, 1093–1103. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  107. Perez-Mana, C.; Farre, M.; Rodriguez-Morato, J.; Papaseit, E.; Pujadas, M.; Fito, M.; Robledo, P.; Covas, M.I.; Cheynier, V.; Meudec, E.; et al. Moderate consumption of wine, through both its phenolic compounds and alcohol content, promotes hydroxytyrosol endogenous generation in humans. A randomized controlled trial. Mol. Nutr. Food Res. 2015, 59, 1213–1216. [Google Scholar] [CrossRef] [PubMed]
  108. Barden, A.E.; Croft, K.D.; Beilin, L.J.; Phillips, M.; Ledowski, T.; Puddey, I.B. Acute effects of red wine on cytochrome P450 eicosanoids and blood pressure in men. J. Hypertens 2013, 31, 2195–2202. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  109. Kiviniemi, T.O.; Saraste, A.; Lehtimaki, T.; Toikka, J.O.; Saraste, M.; Raitakari, O.T.; Hartiala, J.J.; Viikari, J.; Koskenvuo, J.W. Decreased endothelin-1 levels after acute consumption of red wine and de-alcoholized red wine. Atherosclerosis 2010, 211, 283–286. [Google Scholar] [CrossRef]
  110. Kiviniemi, T.O.; Saraste, A.; Lehtimaki, T.; Toikka, J.O.; Saraste, M.; Raitakari, O.T.; Parkka, J.P.; Hartiala, J.J.; Viikari, J.; Koskenvuo, J.W. High dose of red wine elicits enhanced inhibition of fibrinolysis. Eur J Cardiovasc. Prev. Rehabil. 2009, 16, 161–163. [Google Scholar] [CrossRef]
  111. Kiviniemi, T.O.; Saraste, A.; Toikka, J.O.; Saraste, M.; Raitakari, O.T.; Parkka, J.P.; Lehtimaki, T.; Hartiala, J.J.; Viikari, J.; Koskenvuo, J.W. A moderate dose of red wine, but not de-alcoholized red wine increases coronary flow reserve. Atherosclerosis 2007, 195, e176–e181. [Google Scholar] [CrossRef]
  112. Modun, D.; Music, I.; Vukovic, J.; Brizic, I.; Katalinic, V.; Obad, A.; Palada, I.; Dujic, Z.; Boban, M. The increase in human plasma antioxidant capacity after red wine consumption is due to both plasma urate and wine polyphenols. Atherosclerosis 2008, 197, 250–256. [Google Scholar] [CrossRef]
  113. Karatzi, K.; Papamichael, C.; Karatzis, E.; Papaioannou, T.G.; Voidonikola, P.T.; Lekakis, J.; Zampelas, A. Acute smoking induces endothelial dysfunction in healthy smokers. Is this reversible by red wine’s antioxidant constituents? J. Am. Coll. Nutr. 2007, 26, 10–15. [Google Scholar] [CrossRef]
  114. Boban, M.; Modun, D.; Music, I.; Vukovic, J.; Brizic, I.; Salamunic, I.; Obad, A.; Palada, I.; Dujic, Z. Red wine induced modulation of vascular function: Separating the role of polyphenols, ethanol, and urates. J. Cardiovasc. Pharmacol. 2006, 47, 695–701. [Google Scholar] [CrossRef] [Green Version]
  115. Karatzi, K.N.; Papamichael, C.M.; Karatzis, E.N.; Papaioannou, T.G.; Aznaouridis, K.A.; Katsichti, P.P.; Stamatelopoulos, K.S.; Zampelas, A.; Lekakis, J.P.; Mavrikakis, M.E. Red wine acutely induces favorable effects on wave reflections and central pressures in coronary artery disease patients. Am. J. Hypertens 2005, 18, 1161–1167. [Google Scholar] [CrossRef] [Green Version]
  116. Pal, S.; Naissides, M.; Mamo, J. Polyphenolics and fat absorption. Int. J. Obes. Relat. Metab. Disord. 2004, 28, 324–326. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  117. Papamichael, C.; Karatzis, E.; Karatzi, K.; Aznaouridis, K.; Papaioannou, T.; Protogerou, A.; Stamatelopoulos, K.; Zampelas, A.; Lekakis, J.; Mavrikakis, M. Red wine’s antioxidants counteract acute endothelial dysfunction caused by cigarette smoking in healthy nonsmokers. Am. Heart J. 2004, 147, E5. [Google Scholar] [CrossRef]
  118. Watzl, B.; Bub, A.; Briviba, K.; Rechkemmer, G. Acute intake of moderate amounts of red wine or alcohol has no effect on the immune system of healthy men. Eur. J. Nutr. 2002, 41, 264–270. [Google Scholar] [CrossRef] [PubMed]
  119. Bub, A.; Watzl, B.; Heeb, D.; Rechkemmer, G.; Briviba, K. Malvidin-3-glucoside bioavailability in humans after ingestion of red wine, dealcoholized red wine and red grape juice. Eur. J. Nutr. 2001, 40, 113–120. [Google Scholar] [CrossRef] [PubMed]
  120. Bell, J.R.; Donovan, J.L.; Wong, R.; Waterhouse, A.L.; German, J.B.; Walzem, R.L.; Kasim-Karakas, S.E. (+)-Catechin in human plasma after ingestion of a single serving of reconstituted red wine. Am. J. Clin. Nutr. 2000, 71, 103–108. [Google Scholar] [CrossRef] [PubMed]
  121. Caccetta, R.A.; Croft, K.D.; Beilin, L.J.; Puddey, I.B. Ingestion of red wine significantly increases plasma phenolic acid concentrations but does not acutely affect ex vivo lipoprotein oxidizability. Am. J. Clin. Nutr. 2000, 71, 67–74. [Google Scholar] [CrossRef] [Green Version]
  122. Agewall, S.; Wright, S.; Doughty, R.N.; Whalley, G.A.; Duxbury, M.; Sharpe, N. Does a glass of red wine improve endothelial function? Eur. Heart J. 2000, 21, 74–78. [Google Scholar] [CrossRef]
  123. Donovan, J.L.; Bell, J.R.; Kasim-Karakas, S.; German, J.B.; Walzem, R.L.; Hansen, R.J.; Waterhouse, A.L. Catechin is present as metabolites in human plasma after consumption of red wine. J. Nutr. 1999, 129, 1662–1668. [Google Scholar] [CrossRef]
  124. Yang, C.S.; Ho, C.T.; Zhang, J.; Wan, X.; Zhang, K.; Lim, J. Antioxidants: Differing Meanings in Food Science and Health Science. J. Agric. Food Chem. 2018, 66, 3063–3068. [Google Scholar] [CrossRef]
  125. Gorelik, S.; Ligumsky, M.; Kohen, R.; Kanner, J. The stomach as a “bioreactor”: When red meat meets red wine. J. Agric. Food Chem. 2008, 56, 5002–5007. [Google Scholar] [CrossRef] [PubMed]
  126. Timmers, P.; Wilson, J.F.; Joshi, P.K.; Deelen, J. Multivariate genomic scan implicates novel loci and haem metabolism in human ageing. Nat. Commun. 2020, 11, 3570. [Google Scholar] [CrossRef] [PubMed]
  127. Tirosh, O.; Shpaizer, A.; Kanner, J. Lipid Peroxidation in a Stomach Medium Is Affected by Dietary Oils (Olive/Fish) and Antioxidants: The Mediterranean versus Western Diet. J. Agric. Food Chem. 2015, 63, 7016–7023. [Google Scholar] [CrossRef] [PubMed]
  128. Natella, F.; Ghiselli, A.; Guidi, A.; Ursini, F.; Scaccini, C. Red wine mitigates the postprandial increase of LDL susceptibility to oxidation. Free Radic. Biol. Med. 2001, 30, 1036–1044. [Google Scholar] [CrossRef]
  129. Kanner, J.; Gorelik, S.; Roman, S.; Kohen, R. Protection by polyphenols of postprandial human plasma and low-density lipoprotein modification: The stomach as a bioreactor. J. Agric. Food Chem. 2012, 60, 8790–8796. [Google Scholar] [CrossRef]
  130. Kanner, J.; Selhub, J.; Shpaizer, A.; Rabkin, B.; Shacham, I.; Tirosh, O. Redox homeostasis in stomach medium by foods: The Postprandial Oxidative Stress Index (POSI) for balancing nutrition and human health. Redox. Biol. 2017, 12, 929–936. [Google Scholar] [CrossRef]
  131. Ellinger, S.; Muller, N.; Stehle, P.; Ulrich-Merzenich, G. Consumption of green tea or green tea products: Is there an evidence for antioxidant effects from controlled interventional studies? Phytomedicine 2011, 18, 903–915. [Google Scholar] [CrossRef]
  132. Higdon, J.V.; Frei, B. Coffee and health: A review of recent human research. Crit. Rev. Food Sci. Nutr. 2006, 46, 101–123. [Google Scholar] [CrossRef]
  133. van Dam, R.M.; Hu, F.B.; Willett, W.C. Coffee, Caffeine, and Health. N. Engl. J. Med. 2020, 383, 369–378. [Google Scholar] [CrossRef]
  134. Comporti, M.; Signorini, C.; Leoncini, S.; Gardi, C.; Ciccoli, L.; Giardini, A.; Vecchio, D.; Arezzini, B. Ethanol-induced oxidative stress: Basic knowledge. Genes Nutr. 2010, 5, 101–109. [Google Scholar] [CrossRef] [Green Version]
  135. Wynder, E.L.; Higgins, I.T.; Harris, R.E. The wish bias. J. Clin. Epidemiol. 1990, 43, 619–621. [Google Scholar] [CrossRef]
  136. Ioannidis, J.P. We need more randomized trials in nutrition-preferably large, long-term, and with negative results. Am. J. Clin. Nutr. 2016, 103, 1385–1386. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  137. Trepanowski, J.F.; Ioannidis, J.P.A. Perspective: Limiting Dependence on Nonrandomized Studies and Improving Randomized Trials in Human Nutrition Research: Why and How. Adv. Nutr. 2018, 9, 367–377. [Google Scholar] [CrossRef] [PubMed]
  138. Laville, M.; Segrestin, B.; Alligier, M.; Ruano-Rodriguez, C.; Serra-Majem, L.; Hiesmayr, M.; Schols, A.; La Vecchia, C.; Boirie, Y.; Rath, A.; et al. Evidence-based practice within nutrition: What are the barriers for improving the evidence and how can they be dealt with? Trials 2017, 18, 425. [Google Scholar] [CrossRef] [PubMed]
  139. Visioli, F. Can experimental pharmacology be always applied to human nutrition? Int. J. Food Sci. Nutr. 2012, 63 (Suppl. 1), 10–13. [Google Scholar] [CrossRef]
Molecules 25 04105 g001 550
Figure 1. Schematic overview of current pitfalls in wine (poly)phenols research.
Figure 1. Schematic overview of current pitfalls in wine (poly)phenols research.
Molecules 25 04105 g001
Table
Table 1. Classification of phenolic compounds found in wine.
Table 1. Classification of phenolic compounds found in wine.
GroupSubgroupMain Parent Compounds and Representative Derivatives
Flavonoids
Molecules 25 04105 i001		 Molecules 25 04105 i002 Molecules 25 04105 i003
Molecules 25 04105 i004 Molecules 25 04105 i005
Molecules 25 04105 i006 Molecules 25 04105 i007
Molecules 25 04105 i008 Molecules 25 04105 i009
Molecules 25 04105 i010 Molecules 25 04105 i011
Molecules 25 04105 i012 Molecules 25 04105 i013
Non-flavonoids Molecules 25 04105 i014 Molecules 25 04105 i015
Molecules 25 04105 i016 Molecules 25 04105 i017
Molecules 25 04105 i018 Molecules 25 04105 i019
Table
Table 2. Range of total phenolic content in red and white wines in a representative set of studies.
Table 2. Range of total phenolic content in red and white wines in a representative set of studies.
Red Wine White Wine
Total Phenolic Content a Total Phenolic Content a
Range Range
Min.Max.nMin.Max.n Reference
1615417772168547[16]
13132389168940717[17]
2193318362924024[18]
622320020---[19]
1724193652824345[15]
2340373023---[20]
146033803921039047[21]
2082318432132775[22]
140231802418942511[14]
320059008---[23]
1788307045537020[24]
1012326411---[25]
554266921673473[26]
1181358923---[27]
---291210314[28]
86027108---[29]
160219687---[30]
183734676---[31]
89663193877832[32]
Mean ± SD1538 ± 6643406 ± 1139 189 ± 85554 ± 545
Median (Q25–Q75)1531
(983–1898)		3192
(2700–3624)		 210
(89–282)		402
(347–434)
a Data are expressed as gallic acid equivalents (GAE) in mg/L.
Table
Table 3. (Poly)phenol contents in red and white wines.
Table 3. (Poly)phenol contents in red and white wines.
Red WineWhite Wine
Phenol Explorer aUSDA bPhenol Explorer aUSDA b
meanminmaxmeanminmaxmeanminmaxmeanminmax
FlavonoidsMain representatives
AnthocyaninsCyanidin c2.90.611.91.90.045.0------
Delphinidin c16.62.440.120.10.257.1------
Malvidin c15612.45411380.05360.40.03.50.60.02.4
Peodinin c18.12.580.912.50.250.3------
Petunidin c23.63.461.819.80.256.6------
Total 21721.37361930.67450.40.03.50.60.02.4
DihydroflavonolsDihydromyricetin 3-O-rhamnoside44.744.744.7---3.03.03.0---
Total 54.445.859.8---5.73.715.9---
Flavanols(+)-Catechin68.113.839071.40.039010.80.046.07.70.058.0
(-)-Epicatechin37.80.016537.90.01659.50.060.05.50.560.0
Proanthocyanidins35599.756029663.113540.20.01.53.90.67.3
Total 470114113140763.1191720.80.010917.11.1125
FlavanonesNaringenin c8.07.38.817.710.325.12.31.72.93.80.07.7
Total 8.57.89.424.013.035.02.31.72.97.83.212.5
FlavonesApigenin---1.30.04.7------
Total ---1.70.08.7------
FlavonolsIsorhamnetin c5.91.711.60.20.01.60.00.00.00.00.00.2
Kaempferol c10.25.714.40.90.013.70.20.02.60.10.02.7
Myricetin c8.30.017.94.20.017.90.00.00.00.10.01.0
Quercetin c44.212.311010.40.033.64.61.320.80.40.08.4
Total 68.619.715415.70.066.84.81.323.40.50.09.4
Non-flavonoids
Hydroxybenzoic acidsGallic 35.90.0126NANANA2.20.011.0NANANA
Gentisic4.60.08.0NANANA18.20.020.0NANANA
Protocatechuic 1.70.09.6NANANA3.30.113.0NANANA
Syringic 2.70.023.3NANANA0.50.00.2NANANA
Vanillic 3.20.07.5NANANA0.40.11.2NANANA
Total 70.113.7221NANANA24.80.446.8NANANA
Hydroxycinnamic acidsCaffeic18.80.077.0NANANA2.40.07.0NANANA
Caftaric33.51.4179NANANA21.521.422.0NANANA
Ferulic0.80.010.4NANANA0.90.32.1NANANA
(o- and p-) Coumaric5.80.240.4NANANA1.80.05.6NANANA
Sinapic0.70.05.4NANANA0.60.02.8NANANA
Total 10014.9378NANANA28.221.742.4NANANA
StilbenesResveratrol d5.80.061.5NANANA0.90.03.2NANANA
Resveratrol 3-O-glucoside d12.50.088.0NANANA5.00.413.1NANANA
Piceatannol c15.36.338.8NANANA4.61.48.0NANANA
Viniferins (δ-. ε-)7.90.126.7NANANA0.60.00.1NANANA
Pallidol2.00.02.5NANANA0.70.00.3NANANA
Total 43.56.4218NANANA10.61.424.7NANANA
Other polyphenolsHydroxybenzaldehydes7.10.045.6NANANA4.12.45.8NANANA
Tyrosols36.56.454.3NANANA4.22.75.7NANANA
Total 43.66.499.9NANANA8.35.111.5NANANA
a Data are expressed as milligrams of gallic acid equivalent per litter (mg/GAE/L). b Data are expressed as milligrams of gallic acid equivalent per kilogram (mg/GAE/Kg). c Plus glucoside derivatives.d includes both cis and trans conformations. NA, data not available in the database.

Share and Cite

MDPI and ACS Style

Visioli, F.; Panaite, S.-A.; Tomé-Carneiro, J. Wine’s Phenolic Compounds and Health: A Pythagorean View. Molecules 2020, 25, 4105. https://doi.org/10.3390/molecules25184105

AMA Style

Visioli F, Panaite S-A, Tomé-Carneiro J. Wine’s Phenolic Compounds and Health: A Pythagorean View. Molecules. 2020; 25(18):4105. https://doi.org/10.3390/molecules25184105

Chicago/Turabian Style

Visioli, Francesco, Stefan-Alexandru Panaite, and Joao Tomé-Carneiro. 2020. "Wine’s Phenolic Compounds and Health: A Pythagorean View" Molecules 25, no. 18: 4105. https://doi.org/10.3390/molecules25184105

Article Metrics

Back to TopTop